REGENXBIO Inc. (RGNX) — Financial statements
Income statement, balance sheet, and cash flow for REGENXBIO Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 170↑104.5% | 83↓7.7% | 90↓19.9% | 113↓76.0% | 470 | |
| Cost of Revenue | 20↓39.5% | 34↓9.8% | 37↓31.8% | 55↑5.2% | 52 | |
| Gross Profit | 150↑201.7% | 50↓6.2% | 53↓8.9% | 58↓86.1% | 419 | |
| Operating Expenses | ||||||
| R&D Expenses | 228↑9.5% | 209↓10.2% | 232↓4.2% | 242↑33.6% | 181 | |
| General & Administrative Expenses | 83↑8.1% | 77↓13.4% | 88↑3.8% | 85↑7.5% | 79 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 83↑8.1% | 77↓13.4% | 88↑3.8% | 85↑7.5% | 79 | |
| Other Expenses | 0.18↑108.8% | -2↓612.3% | 0.40↑105.9% | -7↓198.7% | -2 | |
| Operating Expenses | 311↑10.0% | 283↓11.8% | 321↑0.0% | 321↑24.2% | 259 | |
| Total Costs & Expenses | 332↑4.7% | 317↓11.6% | 358↓4.6% | 376↑21.0% | 310 | |
| Operating Results | ||||||
| Operating Income | -161↑30.9% | -233↑13.0% | -268↓2.0% | -263↓264.3% | 160 | |
| Depreciation & Amortization | 16↓3.7% | 16↓6.4% | 17↑34.2% | 13↑35.0% | 10 | |
| EBITDA | -146↑26.6% | -198↑17.2% | -239↑2.0% | -244↓244.1% | 170 | |
| EBIT | -161↑24.8% | -214↑16.5% | -257↑0.1% | -257↓260.7% | 160 | |
| Interest & Other Income | ||||||
| Net Interest Income | -33↓162.3% | -12↓82.6% | -7↑70.2% | -23↑10.4% | -26 | |
| Interest Income | 12↑6949.4% | 0.17↑596.0% | 0.03↓92.7% | 0.34↓52.4% | 0.72 | |
| Interest Expense | 45↑255.5% | 13↑84.5% | 7↓70.5% | 23↓11.5% | 26 | |
| Non-Operating Income | 0.00↑100.0% | -19↓66.6% | -11↓98.1% | -6 | 0.00 | |
| Other Income / Expenses | -33↓623.4% | 6↑39.3% | 4↑125.6% | -18↑6.4% | -19 | |
| Income Before Tax | -194↑14.6% | -227↑13.9% | -264↑6.0% | -280↓298.5% | 141 | |
| Income Tax Expense | 0.00 | 0.00↑100.0% | -0.15↓81.0% | -0.08↓100.6% | 13 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -194↑14.6% | -227↑13.8% | -263↑6.0% | -280↓319.3% | 128 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -194↑14.6% | -227↑13.8% | -263↑6.0% | -280↓319.3% | 128 | |
| Bottom-Line Net Income | -194↑14.6% | -227↑13.8% | -263↑6.0% | -280↓319.3% | 128 | |
| EPS (Basic) | -3.76↑18.1% | -4.59↑23.8% | -6.02↑7.4% | -6.50↓315.9% | 3.01 | |
| EPS (Diluted) | -3.76↑18.1% | -4.59↑23.8% | -6.02↑7.4% | -6.50↓323.4% | 2.91 | |
| Weighted Average Shares | 52↑4.2% | 50↑13.2% | 44↑1.3% | 43↑1.7% | 42 | |
| Weighted Average Diluted Shares | 52↑4.2% | 50↑13.2% | 44↑1.3% | 43↓1.7% | 44 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.